Detailed information for compound 427251

Basic information

Technical information
  • TDR Targets ID: 427251
  • Name: 2-[5-[[2-[5-cyclohexyl-1-(3,3-dimethyl-2-oxob utyl)-2-oxo-1,3,4-benzotriazepin-3-yl]acetyl] amino]indol-1-yl]acetic acid
  • MW: 571.667 | Formula: C32H37N5O5
  • H donors: 2 H acceptors: 5 LogP: 5.02 Rotable bonds: 10
    Rule of 5 violations (Lipinski): 2
  • SMILES: O=C(Cn1nc(C2CCCCC2)c2c(n(c1=O)CC(=O)C(C)(C)C)cccc2)Nc1ccc2c(c1)ccn2CC(=O)O
  • InChi: 1S/C32H37N5O5/c1-32(2,3)27(38)18-36-26-12-8-7-11-24(26)30(21-9-5-4-6-10-21)34-37(31(36)42)19-28(39)33-23-13-14-25-22(17-23)15-16-35(25)20-29(40)41/h7-8,11-17,21H,4-6,9-10,18-20H2,1-3H3,(H,33,39)(H,40,41)
  • InChiKey: ONZZXSSEWMDVCA-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 2-[5-[[2-[5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,3,4-benzotriazepin-3-yl]acetyl]amino]indol-1-yl]acetic acid
  • 2-[5-[[2-[5-cyclohexyl-1-(3,3-dimethyl-2-oxobutyl)-2-oxo-1,3,4-benzotriazepin-3-yl]-1-oxoethyl]amino]-1-indolyl]acetic acid
  • 2-[5-[2-[5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,3,4-benzotriazepin-3-yl]ethanoylamino]indol-1-yl]ethanoic acid
  • 2-[5-[[2-[5-cyclohexyl-2-keto-1-(2-keto-3,3-dimethyl-butyl)-1,3,4-benzotriazepin-3-yl]acetyl]amino]indol-1-yl]acetic acid

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens cholecystokinin B receptor Starlite/ChEMBL References
Homo sapiens cholecystokinin A receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Brugia malayi sulfakinin receptor protein Get druggable targets OG5_132882 All targets in OG5_132882
Brugia malayi hypothetical protein Get druggable targets OG5_132882 All targets in OG5_132882
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_132882 All targets in OG5_132882
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus rhodopsin orphan GPCR cholecystokinin A receptor 428 aa 373 aa 19.6 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Treponema pallidum phospho-N-acetylmuramoyl-pentapeptide-transferase (mraY) 0.0288 0.1794 0.5
Loa Loa (eye worm) hypothetical protein 0.0261 0.1324 0.5
Echinococcus multilocularis thymidine phosphorylase 0.0657 0.8234 0.5
Echinococcus granulosus thymidine phosphorylase 0.0657 0.8234 0.5
Mycobacterium ulcerans phospho-N-acetylmuramoyl-pentapeptide-transferase 0.0758 1 1
Mycobacterium tuberculosis Probable thymidine phosphorylase DeoA (tdrpase) (pyrimidine phosphorylase) 0.0657 0.8234 0.8234
Wolbachia endosymbiont of Brugia malayi phospho-N-acetylmuramoyl-pentapeptide-transferase 0.0758 1 0.5
Brugia malayi hypothetical protein 0.0261 0.1324 0.5
Mycobacterium tuberculosis Probable phospho-N-acetylmuramoyl-pentappeptidetransferase MurX 0.0758 1 1
Chlamydia trachomatis phospho-N-acetylmuramoyl-pentapeptide-transferase 0.0288 0.1794 0.5
Brugia malayi sulfakinin receptor protein 0.0261 0.1324 0.5
Mycobacterium ulcerans thymidine phosphorylase 0.0657 0.8234 0.8234

Activities

Activity type Activity value Assay description Source Reference
Ki (binding) = -9.11 Displacement of [3H]BH-CCK-8S from human recombinant CCK2 receptor expressed in NIH3T3 cells ChEMBL. 17536796
Ki (binding) = -5.6 Displacement of [3H]L-364,718 from human recombinant CCK1 receptor expressed in CHOK1 cells ChEMBL. 17536796
Log Ki (binding) = 5.6 Displacement of [3H]L-364,718 from human recombinant CCK1 receptor expressed in CHOK1 cells ChEMBL. 17536796
Log Ki (binding) = 9.11 Displacement of [3H]BH-CCK-8S from human recombinant CCK2 receptor expressed in NIH3T3 cells ChEMBL. 17536796

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.